Last updated: February 16, 2026
What is the current market status of NDC: 65162-0681?
NDC 65162-0681 is marketed as Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is developed by Eli Lilly and approved by the FDA in May 2022 for type 2 diabetes management. Tirzepatide is marketed under the brand name Mounjaro.
As of 2023, Tirzepatide holds a dominant position within the GLP-1 receptor agonist segment due to competitive efficacy, having secured significant market share against rivals like semaglutide (Ozempic, Wegovy). Its revenue potential is high due to the expanding prevalence of type 2 diabetes and obesity.
How is Tirzepatide positioned within the competitive landscape?
| Product |
Company |
Indication |
Approval Date |
Market Share (2023) |
Annual Sales (2023) |
Price (per dose) |
| Mounjaro |
Eli Lilly |
Type 2 diabetes, obesity |
May 2022 |
Estimated > 60% |
~$2.4 billion |
~$1,000 |
| Ozempic (semaglutide) |
Novo Nordisk |
Type 2 diabetes, weight loss |
Dec 2017 |
25-30% |
~$3.0 billion |
~$900 |
| Wegovy |
Novo Nordisk |
Obesity |
Jun 2021 |
10-15% |
~$2.0 billion |
~$1,000 |
Tirzepatide’s unique dual mechanism offers advantages in efficacy, leading to a rapid uptake among clinicians. Market dominance is expected to continue as ongoing clinical trials extend indications to weight management and cardiovascular risk reduction.
What are the price trends for Tirzepatide?
The current standard per-dose retail price for Tirzepatide is approximately $1,000. This aligns with pricing for similar medications in the class, reflecting high R&D costs, substantial clinical value, and premium positioning.
Projected pricing may face pressure as competitors introduce biosimilars or alternative therapies. However, as a first-in-class drug with patent protection scheduled into the mid-2030s, significant price erosion is not imminent.
What are the key factors influencing future prices?
- Patent protection and exclusivity: Patents extend until 2036, preventing generic competition.
- Clinical trial outcomes: Positive results in cardiovascular and obesity indications can sustain premium pricing.
- Reimbursement policies: Insurance coverage influences patient access and pricing flexibility.
- Market demand: Increasing prevalence of type 2 diabetes and obesity supports steady sales growth.
What is the forecast for Tirzepatide revenues?
| Year |
Revenue Estimate |
Change Rate |
Notes |
| 2023 |
~$2.4 billion |
— |
Mature sales with dominant market share. |
| 2024 |
~$3.2 billion |
+33% |
Expansion into obesity and CV indications. |
| 2025 |
~$4.0 billion |
+25% |
Broader acceptance and patient base growth. |
| 2026 |
~$4.8 billion |
+20% |
Potential reimbursement adjustments. |
Analysts project a compound annual growth rate (CAGR) of about 30% until 2026, driven by increasing indications and new formulations.
What are the risks to the market and price projections?
- Regulatory delays: Additional approvals or label expansions could fluctuate revenue.
- Competitive threats: Biosimilar entry post patent expiry, or novel therapies disrupting market share.
- Pricing pressures: Payer negotiations may limit reimbursement levels.
- Clinical outcomes: Failure in ongoing trials for non-approved indications could impact future revenue streams.
Key Takeaways
- Tirzepatide (NDC: 65162-0681) is the leading GIP/GLP-1 receptor agonist, with robust growth since its 2022 approval.
- It commands a premium price (~$1,000 per dose) due to its clinical profile and patent protection.
- Revenue projections suggest rapid growth, potentially surpassing $4 billion annually by 2025.
- Market competition remains intense; biosimilars are expected post-2036.
- Clinical and regulatory developments will heavily influence the pricing trajectory.
FAQs
1. When is Tirzepatide expected to face biosimilar competition?
Biosimilars for the drug class are unlikely until patent expiration around 2036; no biosimilar approvals are anticipated before then.
2. What new indications are in clinical development for Tirzepatide?
Ongoing trials are assessing its efficacy in weight management for obesity and cardiovascular risk reduction, which could expand its market.
3. How does Tirzepatide compare to existing GLP-1 receptor agonists?
It offers superior efficacy in weight loss and glycemic control due to its dual mechanism, potentially positioning it as a preferred therapy.
4. How will reimbursement trends affect Tirzepatide pricing?
Reimbursement will depend on payer acceptance; demonstrated cost-effectiveness could support premium pricing.
5. What are the primary regulatory considerations for Tirzepatide’s future expansion?
FDA and other agencies will evaluate trial outcomes for new indications, with approval timelines influenced by data quality and submission timing.
Sources
- FDA Approval documents for Tirzepatide (May 2022).
- Eli Lilly annual reports and investor presentations (2023).
- Market research reports on GLP-1 receptor agonists (2023).
- Price analysis reports from Neuraxpert and GoodRx (2023).
- ClinicalTrials.gov data on Tirzepatide development phases (2023).
